• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ontrak Inc.

    2/14/24 3:48:52 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care
    Get the next $OTRK alert in real time by email
    SC 13G 1 armistice-otrk123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Ontrak, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    683373302

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  683373302
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,886,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,886,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,886,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.80%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  683373302
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,886,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,886,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,886,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.80%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 683373302
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Ontrak, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    3710 - 33rd Street

    NW Calgary, Alberta

    Canada, T2L 2MI

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.0001 par value (“Shares”)

     

    Item 2.(e) CUSIP No.:

    683373302

     

    CUSIP No.  683373302
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 683373302
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2023:

    Armistice Capital, LLC - 2,886,000

    Steven Boyd - 2,886,000  

    (b) Percent of Class as of December 31, 2023:

    Armistice Capital, LLC - 9.80%

    Steven Boyd - 9.80% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 2,886,000

    Steven Boyd - 2,886,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 2,886,000

    Steven Boyd - 2,886,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 683373302
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 683373302
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $OTRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTRK

    DatePrice TargetRatingAnalyst
    12/5/2023$4.00Buy
    ROTH MKM
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    3/9/2022$11.00 → $2.00Sector Perform
    RBC Capital
    8/20/2021$35.00 → $9.00Market Perform → Underperform
    Cowen & Co.
    8/20/2021$15.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      5/20/25 5:31:02 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      4/1/25 9:24:56 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - Ontrak, Inc. (0001136174) (Issuer)

      1/6/25 8:08:28 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Secures Financing Commitment to Fuel Growth and Innovation

      Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has secured a $10 million financing commitment from Acuitas Capital, LLC. This financing commitment will support Ontrak's continued growth and innovation in delivering comprehensive behavioral healthcare solutions and is structured to provide Ontrak with the necessary capital to expand its customer base while continuing to drive further advancements in its AI and digital capabilities. The commitment contemplates that Ontrak may raise additional financing from third parties to further support its growth initiatives. Brandon LaVerne, Chief Executiv

      5/20/25 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ontrak Inc.

      10-Q - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:08:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:05:48 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 8:02:18 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Ontrak Names James Messina to its Board of Directors

      Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by providing business development, marketing, operating and technology support. Previously, Mr. Messina was the Executive Vice President and Chief Operating Officer for Premera Blue Cross ("Premera"). He was responsible for effectively servicing the needs of Premera's customers with oversight of all operational functions, from customer serv

      8/30/22 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Names Dr. Robert Accordino Chief Medical Officer

      Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak's Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company's most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "Dr. Accordino's reputation in

      9/9/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Arik Hill Joins Ontrak as Chief Information Officer

      Former Accenture and KPMG Healthcare Expert Brings Proven Leadership Experience In Behavioral Health Digital Transformation Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Arik Hill as Ontrak's first Chief Information Officer, effective August 30, 2021. Mr. Hill will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "As Chief Information Officer at The New York Foundling, a fast growing organization that collaborates with over 250,000 behavioral healthcare partners across the country, Arik led the development of digital platforms and applications th

      8/12/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

      SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

      11/14/24 4:24:03 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      10/3/24 6:37:08 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      8/30/24 5:15:15 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ontrak with a new price target

      ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

      12/5/23 8:03:01 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Canaccord Genuity reiterated coverage on Ontrak with a new price target

      Canaccord Genuity reiterated coverage of Ontrak with a rating of Hold and set a new price target of $2.50 from $13.00 previously

      3/9/22 9:09:19 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Ontrak with a new price target

      RBC Capital reiterated coverage of Ontrak with a rating of Sector Perform and set a new price target of $2.00 from $11.00 previously

      3/9/22 7:43:55 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Financials

    Live finance-specific insights

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the fourth quarter 2024 on Monday, April 14, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/delivering-a-healthier-future-for-all/presentations-events/. Participants interested in dialing in to the conference call are requested to register a day in advance or

      4/10/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care